| Old Articles: <Older 7511-7520 Newer> |
 |
The Motley Fool May 23, 2005 W.D. Crotty |
M'm! M'm! Better Than Nothing Campbell's reports bland quarterly results. Investors, take note.  |
The Motley Fool May 23, 2005 Jeremy MacNealy |
Wild Wings' Migration Buffalo Wild Wings' eggs continue to hatch as the company expands. Investors looking to add to their positions in the restaurant may still be feeling the sting from the company's first-quarter disappointment.  |
The Motley Fool May 23, 2005 John Reeves |
The Best Analyst Money Can Buy One of the keys to successful investing is knowledge. For other stocks that may or may not become value opportunities in the future, it would be ideal if you did your homework ahead of time. That way, you are ready when the situation arises.  |
The Motley Fool May 23, 2005 Alyce Lomax |
Intel Inside Apple? An old rumor results in some new stock price gains. Investor, beware. This Apple/Intel idea is a common rumor that seems to reappear every so often.  |
The Motley Fool May 23, 2005 Nathan Parmelee |
Deb Shops: Dividend Diva The company pairs a one-time dividend with an already robust payout, a solid balance sheet, and margin improvements.  |
The Motley Fool May 23, 2005 Stephen D. Simpson |
Why Not Watch SBS Broadcasting? This European TV provider continues to make progress with its digital and pay TV initiatives. It look like a good stock, but you must do your own due diligence.  |
The Motley Fool May 23, 2005 Mathew Emmert |
Dividends From a Tech Stock? Microsoft has the potential for monster dividend growth.  |
The Motley Fool May 23, 2005 Alyce Lomax |
Gap's Fashion Sense Is the retailer's fashion sense on the blink? Investors, take note.  |
The Motley Fool May 23, 2005 Rich Smith |
Lifeway on Ice The up-and-coming dairy puts profits growth in the fridge. If only free cash flow and profits growth could again match that performance, Lifeway would rise to become the cream of the dairy industry's crop.  |
The Motley Fool May 23, 2005 Jack Uldrich |
Releasing Nanotech's Potential? Recent developments at pSivida suggest a turnaround for the biomedical nanotech company from Down Under.  |
| <Older 7511-7520 Newer> Return to current articles. |